Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dolutegravir + carbamazepine is a non-coformulated combination in which both drugs are taken together for clinical reasons, often in patients with HIV requiring antiretroviral therapy alongside treatment for seizures or neuropathic pain. Dolutegravir is an integrase strand transfer inhibitor that prevents HIV-1 viral DNA from integrating into the host genome, blocking viral replication. Carbamazepine is an anticonvulsant and mood-stabilizer that works by stabilizing the inactivated state of voltage-gated sodium channels in the central nervous system, reducing neuronal excitability. When administered together, carbamazepine—being a strong inducer of CYP3A4 and UGT1A1—markedly lowers dolutegravir plasma levels by increasing its metabolism, which may compromise HIV treatment efficacy[3][5][9]. Dose adjustment of dolutegravir (typically to twice daily) is recommended when given with carbamazepine to maintain therapeutic levels. This interaction does not represent a fixed-dose combination, but clinically relevant co-administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dolutegravir + carbamazepine.